Y Mabs Therapeutics Stock Today
| YMAB Stock | USD 10.01 0.27 2.63% |
Performance0 of 100
| Odds Of DistressOver 54
|
Y MAbs is trading at 10.01 as of the 11th of December 2024, a 2.63 percent down since the beginning of the trading day. The stock's open price was 10.28. Y MAbs has 54 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. The performance scores are derived for the period starting the 11th of November 2024 and ending today, the 11th of December 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 21st of September 2018 | Category Healthcare | Classification Health Care |
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York. The company has 44.79 M outstanding shares of which 3.63 M shares are at this time shorted by private and institutional investors with about 13.91 trading days to cover. More on Y mAbs Therapeutics
Moving together with YMAB Stock
Moving against YMAB Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
YMAB Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CEO | Michael Rossi | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsY MAbs can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Y MAbs' financial leverage. It provides some insight into what part of Y MAbs' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Y mAbs Therapeutics (YMAB) is traded on NASDAQ Exchange in USA. It is located in 230 Park Avenue, New York, NY, United States, 10169 and employs 100 people. Y MAbs is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 460.43 M. Y mAbs Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 44.79 M outstanding shares of which 3.63 M shares are at this time shorted by private and institutional investors with about 13.91 trading days to cover.
Y mAbs Therapeutics currently holds about 133.66 M in cash with (27.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.06.
Check Y MAbs Probability Of Bankruptcy
Ownership AllocationY mAbs Therapeutics retains a total of 44.79 Million outstanding shares. The majority of Y MAbs outstanding shares are owned by institutional investors. These institutions are usually referred to as non-private investors looking to purchase positions in Y mAbs Therapeutics to benefit from reduced commissions. Therefore, other corporate entities are subject to a different set of regulations than regular investors in Y mAbs Therapeutics. Please pay attention to any change in the institutional holdings of Y mAbs Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company shows, if the real value of the entity is less than the current market value, you may not be able to make money on it.
Check YMAB Ownership Details
YMAB Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Pictet Asset Manangement Sa | 2024-09-30 | 688 K | |
| Boothbay Fund Management, Llc | 2024-09-30 | 557.4 K | |
| Dimensional Fund Advisors, Inc. | 2024-09-30 | 477.7 K | |
| Soleus Capital Management, L.p. | 2024-09-30 | 400 K | |
| Northern Trust Corp | 2024-09-30 | 337.3 K | |
| Charles Schwab Investment Management Inc | 2024-09-30 | 279.6 K | |
| Citadel Advisors Llc | 2024-09-30 | 274.5 K | |
| Morgan Stanley - Brokerage Accounts | 2024-09-30 | 248.7 K | |
| Goldman Sachs Group Inc | 2024-09-30 | 222.6 K | |
| Paradigm Biocapital Advisors Lp | 2024-09-30 | 4.1 M | |
| Blackrock Inc | 2024-06-30 | 2.9 M |
Y MAbs Historical Income Statement
YMAB Stock Against Markets
Y MAbs Corporate Management
| Courtney Dugan | Vice Relations | Profile | |
| Susan Smith | Senior Officer | Profile | |
| MBBS MBA | Senior Officer | Profile | |
| Torben MSc | VP Operations | Profile | |
| Sue Smith | VP Officer | Profile |
Already Invested in Y mAbs Therapeutics?
The danger of trading Y mAbs Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Y MAbs is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Y MAbs. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Y mAbs Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Y mAbs Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Y MAbs' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Y Mabs Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Y Mabs Therapeutics Stock: Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Y mAbs Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Y MAbs. If investors know YMAB will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Y MAbs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.54) | Revenue Per Share 1.921 | Quarterly Revenue Growth (0.1) | Return On Assets (0.12) | Return On Equity (0.25) |
The market value of Y mAbs Therapeutics is measured differently than its book value, which is the value of YMAB that is recorded on the company's balance sheet. Investors also form their own opinion of Y MAbs' value that differs from its market value or its book value, called intrinsic value, which is Y MAbs' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Y MAbs' market value can be influenced by many factors that don't directly affect Y MAbs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Y MAbs' value and its price as these two are different measures arrived at by different means. Investors typically determine if Y MAbs is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Y MAbs' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.